Nanobiotix (NASDAQ:NBTX) Trading Up 5.7% – Here’s Why

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares were up 5.7% on Monday . The company traded as high as $40.76 and last traded at $40.51. Approximately 114,333 shares were traded during mid-day trading, an increase of 50% from the average daily volume of 76,429 shares. The stock had previously closed at $38.31.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. UBS Group raised their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th. Finally, Leerink Partners boosted their price objective on Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a report on Thursday, June 4th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.33.

Nanobiotix Stock Down 2.3%

The firm’s 50 day simple moving average is $38.07 and its two-hundred day simple moving average is $34.98.

Institutional Investors Weigh In On Nanobiotix

Several institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada grew its position in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares in the last quarter. Marshall Wace LLP acquired a new position in Nanobiotix in the 4th quarter valued at $220,000. Finally, Millennium Management LLC acquired a new position in Nanobiotix in the 4th quarter valued at $390,000. 38.81% of the stock is currently owned by institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.